Nonviral delivery platform for therapeutic RNAi: Pegylated siRNA/cationic liposome complexes for targeting of the proto-oncogene bcl-2

Future Oncology

Volumn 5, Issue 1, 2009, Pages 13-17

  Höbel, Sabrina ^a   Aigner, Achim ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Bcl 2; Cancer; Cationic liposomes; Gene targeting; Gene therapy; Pegylation; RNA interference; RNAi; SiRNA; Small interfering RNA

Indexed keywords

DOCETAXEL; LIPOSOME; NANOPARTICLE; PROTEIN BCL 2; SMALL INTERFERING RNA;

ARTICLE; BIOCOMPATIBILITY; CANCER INHIBITION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG TARGETING; DRUG TISSUE LEVEL; GENE SILENCING; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OVARY CARCINOMA; PERITONEUM METASTASIS; PLASMA HALF LIFE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTO ONCOGENE; RNA INTERFERENCE; SURVIVAL RATE;

EID: 66949166003     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.5.1.13     Document Type: Article

References (14)

1. Sonoke S, Ueda T, Fujiwara K et al.: Tumor regression in mice by delivery of Bcl-2 small interfering RNA with pegylated cationic liposomes. Cancer Res. 68(2), 8843-8845 (2008).
2. Yano J, Hirabayashi K, Nakagawa S et al.: Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin. Cancer Res. 10(22), 7721-7726 (2004).
3. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391(6669), 806-811 (1998).
4. Aigner A: Applications of RNA interference: current state and prospects for siRNA-based. strategies in vivo. Appl. Microbiol. Biotechnol. 76(1), 9-21 (2007).
5. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J: Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov. 6(6), 443-453 (2007).
6. Urban-Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A: RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI) -complexed siRNA in vivo. Gene Ther. 12(5), 461-466 (2005).
7. Minakuchi Y, Takeshita F, Kosaka N et al.: Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res. 32(13), e109 (2004).
8. Howard KA, Rahbek UL, Liu X et al.: RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol. Ther. 14(4), 476-484 (2006).
9. Heidel JD: Linear cyclodextrin-containing polymers and their use as delivery agents. Expert Opin. Drug Deliv. 3(5), 641-646 (2006).
10. Aigner A: Nonviral in vivo delivery of therapeutic small interfering RNAs. Curr. Opin. Mol. Ther. 9(4), 345-352 (2007).
11. Tan PH, Yang LC, Shih HC, Lan KC, Cheng JT: Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-induced nociception in the rat. Gene Ther. 12(1), 59-66 (2005).
12. Kleinman ME, Yamada K, Takeda A et al.: Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452(7187), 591-571 (2008).
13. Robbins M, Judge A, Ambegia E et al.: Misinterpreting the therapeutic effects of siRNA caused by immune stimulation. Hum. Gene Ther. (2008) (Epub ahead of print).
14. Poeck H, Besch R, Maihoefer C et al.: 5′-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat. Med. 14(11), 1256-1263 (2008).